Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients

Sponsor
Federal University of São Paulo (Other)
Overall Status
Completed
CT.gov ID
NCT01730352
Collaborator
Fundação de Amparo à Pesquisa do Estado de São Paulo (Other)
100
4
2
41
25
0.6

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether eradication of Helicobacter pylori infection is effective in the improvement of platelet counts in children and adolescents with chronic ITP.

Condition or Disease Intervention/Treatment Phase
  • Drug: H. pylori triple therapy
Phase 2/Phase 3

Detailed Description

Helicobacter pylori infection has been associated with Immune Thrombocytopenic Purpura (ITP), and there is scientific evidence for the investigation and treatment of this bacterium for adult patients with ITP. However, in children this causal association is not clear, with few published studies.

Study Design

Study Type:
Interventional
Actual Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Helicobacter Pylori Infection and Chronic Immune Thrombocytopenic Purpura in Children and Adolescents - A Randomized Controlled Trial
Study Start Date :
Oct 1, 2008
Actual Primary Completion Date :
May 1, 2011
Actual Study Completion Date :
Mar 1, 2012

Arms and Interventions

Arm Intervention/Treatment
No Intervention: H. pylori no treatment

Observational group, with clinical and platelet count follow-up

Experimental: H. pylori triple therapy

Triple therapy for H. pylori eradication: clarithromycin 15mg/kg, amoxicillin 50mg/kg, furazolidone 7mg/kg and/ or doxycycline 4,4mg/kg (all 2 times per day), with a proton pump inhibitor for 14 days.

Drug: H. pylori triple therapy
Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.
Other Names:
  • Triple therapy for H. pylori
  • H. pylori eradication therapy
  • Pyloripac
  • Outcome Measures

    Primary Outcome Measures

    1. platelet response [1 year]

      Responders: Complete Response (CR), persistent elevation of platelet count to >150×109/L; Partial Response (PR), elevation between 20 and 30×109/L above the baseline values, but between 50 and 149×109/L; No Responders: any of the above categories.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A to 20 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • clinical diagnosis of chronic immune thrombocytopenic purpura

    • children and adolescents up to 20 years

    Exclusion Criteria:
    • known hypersensitivity to any of the drugs

    • recent treatment for H. pylori eradication

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Irmandade da Santa Casa de Misericordia se Sao Paulo Sao Paulo Brazil 01221-020
    2 Centro de Hematologia de Sao Paulo Sao Paulo Brazil 01401-000
    3 Federal University of Sao Paulo Sao Paulo Brazil 04021-001
    4 Hospital Estadual Infantil Darcy Vargas Sao Paulo Brazil 05614-040

    Sponsors and Collaborators

    • Federal University of São Paulo
    • Fundação de Amparo à Pesquisa do Estado de São Paulo

    Investigators

    • Principal Investigator: Elisabete Kawakami, Professor, Federal University of Sao Paulo

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Elisabete Kawakami, Professor, PhD MD, Federal University of São Paulo
    ClinicalTrials.gov Identifier:
    NCT01730352
    Other Study ID Numbers:
    • 08/56706-0
    First Posted:
    Nov 21, 2012
    Last Update Posted:
    Nov 21, 2012
    Last Verified:
    Nov 1, 2012

    Study Results

    No Results Posted as of Nov 21, 2012